A Study of TY-2136b in Patients With Advanced Solid Tumors Harboring ALK, ROS1 or NTRK1-3 Alterations
Status:
Not yet recruiting
Trial end date:
2025-10-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the safety and tolerability of TY-2136b
and to determine the recommended phase 2 dose (RP2D), with dose-escalation stage and
dose-expansion stage.